STOCK TITAN

Cingulate (CING) SEC Filings, Jul 2-20, 2026

CING NASDAQ

Cingulate Inc. filings document a clinical-stage biopharmaceutical issuer developing Precision Timed Release™ drug-delivery products, including CTx-1301 for ADHD, alongside its common stock and warrants listed on Nasdaq. Periodic and current reports furnish operating results, business updates, patent notices, FDA-related program disclosures and research-and-development spending context.

The filing record also covers capital-structure actions such as private placements, preferred stock, warrants, unregistered equity issuances, debt exchanges and at-the-market offering agreements. Proxy and 8-K disclosures address shareholder voting matters, Nasdaq rule compliance, board committee composition, officer appointments, employment agreements and other governance events.

Rhea-AI Summary

Cingulate Inc. granted EVP & Chief Commercial Officer Bryan Wade Downey two stock option awards covering a total of 100,000 shares of common stock, with an exercise price of $4.43 per share and an expiration date of July 16, 2036.

One option for 67,000 shares vests 25% on March 31, 2027, with the remaining shares vesting in substantially equal monthly installments over the following 36 months. A second option for 33,000 shares follows the same vesting schedule but only becomes exercisable if the issuer’s NDA for CTx-1301 is approved by the FDA during 2027; if that NDA is not approved during 2027, this option, including any vested portion, terminates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
insider
-
Rhea-AI Summary

Cingulate Inc. reported that director Lawrence Bryan Jay received a grant of 20,000 Stock Options on 2026-07-16. The options cover 20,000 shares of Common Stock at an exercise price of $4.43 per share, expire on 2036-07-16, and vest on the earlier of the one-year anniversary of grant or the 2027 annual meeting of stockholders. Following this award, Jay holds 20,000 derivative securities directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
insider
-
Rhea-AI Summary

Cingulate Inc. granted stock options to EVP and Chief Medical Officer Matthew Brams on July 16, 2026. He received options to purchase 53,600 and 26,400 shares of common stock at an exercise price of $4.43 per share, expiring on July 16, 2036.

Both option grants vest 25% on March 31, 2027, with the remainder vesting in substantially equal monthly installments over 36 months. The 26,400-share option becomes exercisable only if the issuer’s NDA for CTx-1301 is approved by the FDA during 2027, otherwise the entire option terminates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
insider
Rhea-AI Summary

Cingulate Inc. director Thomas Jeffrey Hargroves received a grant of 20,000 stock options for Common Stock at an exercise price of $4.43 per share. The options vest on the earlier of the one-year anniversary of the grant date and the date of Cingulate’s 2027 annual meeting of stockholders, and expire on 2036-07-16. Following this grant, he holds 20,000 stock options directly. The grant was not reported under a Rule 10b5-1 trading plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
insider
-
Rhea-AI Summary

Cingulate EVP and CFO Jennifer L. Callahan received two grants totaling 60,000 stock options on July 16, 2026, each with an exercise price of $4.4300 per share and expiring July 16, 2036.

For both grants, 25% vests on March 31, 2027, with the remainder vesting in substantially equal monthly installments over the following 36 months. For 19,800 options, vested options become exercisable only if the NDA for CTx-1301 is approved by the FDA during 2027; if that approval is not obtained in 2027, this grant, including any vested portion, terminates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
insider
-
Rhea-AI Summary

Cingulate Inc. director Peter J. Werth received a grant of stock options for 20,000 shares of common stock on July 16, 2026. The options have an exercise price of $4.43 per share and expire on July 16, 2036. They vest on the earlier of the one-year anniversary of the grant date or the date of Cingulate Inc.'s 2027 annual meeting of stockholders, leaving Werth with 20,000 stock options held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
insider
Rhea-AI Summary

Cingulate Inc. EVP and CSO Raul R. Silva received two stock option grants on July 16, 2026. One covers 53,600 shares and the other 26,400 shares of common stock at an exercise price of $4.4300 per share, expiring July 16, 2036. Both vest 25% on March 31, 2027 and then in substantially equal monthly installments over 36 months. The second grant becomes exercisable only if the issuer’s NDA for CTx-1301 is approved by the FDA during 2027; otherwise that option, including any vested portion, terminates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
insider
-
Rhea-AI Summary

Cingulate Inc. held its 2026 Annual Meeting on July 9, 2026, where stockholders approved Amendment No. 3 to the 2021 Omnibus Equity Incentive Plan, increasing shares of common stock authorized for issuance under the plan by 625,000 to a total of 2,221,126 shares.

The Board reduced its size to five directors, appointed Chief Executive Officer Shane Schaffer as chairman, and named director Jeff Hargroves as lead independent director. Committee leadership was reorganized, with Zhanpeng “Frederick” Jiang chairing the Audit Committee, Hargroves chairing the Nominating and Corporate Governance Committee, and Bryan Lawrence chairing the Compensation Committee. Stockholders elected Hargroves as a Class II director and ratified KPMG LLP as independent registered public accounting firm for 2026, while also approving but not using authority to adjourn the meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
current report
-
Rhea-AI Summary

Cingulate Inc. reported that EVP and CSO Raul R. Silva received a grant of stock options as part of his compensation. The award covers options for 3,885 shares of common stock at an exercise price of $5.47 per share, expiring in 2036. These options were granted pursuant to Dr. Silva's employment agreement and increase his potential equity exposure but do not represent an open-market purchase or sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
insider
Rhea-AI Summary

Cingulate Inc. reported two corporate updates. Its subsidiary Cingulate Therapeutics LLC amended the employment agreement with Executive Vice President and Chief Medical Officer Matthew N. Brams, extending his full-time employment trial period from June 30, 2026 to September 30, 2026. The company also announced it has been added to the Russell 3000E® Index, which tracks the performance of approximately 4,000 of the largest investable U.S. equities and is fully reconstituted each June. The press release highlights Cingulate’s focus on its lead ADHD candidate CTx-1301 and its proprietary Precision Timed Release platform, which is designed to deliver medication in multiple timed doses over the day.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.66%
Tags
current report

FAQ

How many Cingulate (CING) SEC filings are available on StockTitan?

StockTitan tracks 71 SEC filings for Cingulate (CING), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Cingulate (CING)?

The most recent SEC filing for Cingulate (CING) was filed on November 13, 2026.